Latest / Trojan Talks / Ep. 12: President Kim with Paul Aisen and Steve Shapiro
Transcript
- 0:03Welcome to Trojan Talks.
- 0:04I'm Beong-Soo Kim, president of the University of Southern California,
- 0:08and this podcast is a space for open conversation with thought
- 0:11leaders, both inside and beyond our university,
- 0:13as we explore the ideas shaping USC's future.
- 0:17During this audio-only episode of Trojan Talks, I'm
- 0:20joined by two renowned USC physician-scientists.
- 0:24The first is Dr.
- 0:25Paul Aisen, director of the USC Epstein Family
- 0:29Alzheimer’s Therapeutic Research Institute,
- 0:32one of the world's leading
- 0:34researchers in Alzheimer's disease.
- 0:36Dr.
- 0:36Aisen and his team at ATRI are conducting
- 0:40some of the most important clinical trials in the country,
- 0:43aimed at developing a cure for Alzheimer's disease
- 0:46within the next 10 years.
- 0:49Joining me in the conversation with Dr.
- 0:50Aisen is Dr.
- 0:52Steve Shapiro, USC's
- 0:54executive vice president of health affairs.
- 0:56Steve is a renowned physician-scientist in the field of pulmonology,
- 1:00and he's also the CEO
- 1:02of Keck Medicine of USC,
- 1:04which treats some of the most complex
- 1:05cases in the nation.
- 1:07During this episode,
- 1:09you'll not only learn about
- 1:10how much progress we've made in understanding
- 1:12and treating Alzheimer's disease,
- 1:14but also the opportunities
- 1:15we see at USC and Keck Medicine
- 1:18to change the future of healthcare.
- 1:21This live recording was taped
- 1:22during a recent Trojan Family reception
- 1:25in La Jolla, California.
- 1:27Please enjoy.
- 1:28Dr.
- 1:28Paul Aisen is one of the world's
- 1:32most respected researchers
- 1:34in the field of Alzheimer's
- 1:36research and, and clinical trials.
- 1:40He has been working for over 40 years
- 1:45to try to understand and cure
- 1:48this disease that has impacted, in one way or another,
- 1:51every single person in this room.
- 1:54And over the last couple of years,
- 1:58thanks to Paul's work,
- 1:59thanks to the support from the Epstein family,
- 2:02thanks to the support of so many other donors,
- 2:05thanks to the collaborative effort we're making
- 2:08with our incredible colleagues from UCSD,
- 2:11I see John and some others back there ...
- 2:15thank you for coming, we have made incredible progress,
- 2:19and we see a cure within the next 10 years.
- 2:23And so Dr.
- 2:24Aisen is going to be talking about that.
- 2:30But before my friend Paul speaks,
- 2:32I'm going to be asking some questions to Dr.
- 2:35Steve Shapiro.
- 2:36Steve is the executive vice
- 2:39president of our academic medical enterprise.
- 2:43That means the hospitals that treat
- 2:46some of the most complex cases in the entire nation
- 2:49and that, by the way, also generate
- 2:53almost half of USC's total revenue.
- 2:56Steve oversees, as the CEO,
- 2:59as of today, those hospitals
- 3:01and also oversees the medical school.
- 3:05And his job is to bring all of this together
- 3:09in a way that cures
- 3:12patients, treats patients
- 3:13who are suffering from the most serious illnesses,
- 3:16and delivers breakthrough
- 3:19discovery and innovation
- 3:21through our medical research.
- 3:23And just by way of background,
- 3:26Steve is a renowned physician-scientist
- 3:29in the field of pulmonology and critical care
- 3:32and also comes to us most recently
- 3:35from the University of Pittsburgh Medical Center,
- 3:37where he oversaw 42 hospitals.
- 3:41So pretty impressive.
- 3:42And so, Steve, let me just
- 3:45ask you a question.
- 3:47For those of,
- 3:49members of the audience, and we are down in San Diego.
- 3:51I hope some of you have experienced the incredible care
- 3:55that we provide at Keck Medicine of USC.
- 3:57But can you just give an overview
- 3:59of Keck Medicine of USC
- 4:02and what makes it so special and distinctive in the country?
- 4:05Thanks, Beong, and great
- 4:07to be down here, everyone.
- 4:09USC has the oldest medical school in the region.
- 4:12We've been taking care of patients at the county hospital
- 4:15for 130 years, Children's Hospital of L.A.
- 4:18since the 1930s, but the youngest health system.
- 4:21USC didn't own a hospital until 2009.
- 4:24But in the short period of time as it's grown,
- 4:27Keck Medical Center, our flagship hospital,
- 4:31takes care of the most complex patients in the country.
- 4:34Case mix index of 3.4.
- 4:35That's not just subjective.
- 4:37They measure this at CMS,
- 4:39with top eight in quality
- 4:41among academic medical centers.
- 4:43And number one or two in patient satisfaction.
- 4:45So we've really distinguished ourselves to have a great culture
- 4:49and care for the most complex and vulnerable patients
- 4:52at a high level, and we're really proud of that.
- 4:54Now, when people think about what you just said,
- 4:57Steve, in terms of the most complex cases.
- 5:01Tell us a little
- 5:02bit more about the advantages that come from
- 5:05being part of not just receiving the treatment,
- 5:08not just from another hospital,
- 5:11which could be a for-profit hospital,
- 5:13but from an academic medical center
- 5:15that is at the forefront
- 5:18of discovery and innovations.
- 5:20How does that translate to a patient?
- 5:23We like to think of this
- 5:25as sort of the virtuous
- 5:27cycle of academic medical centers.
- 5:29We start with great clinical care,
- 5:31which brings in resources,
- 5:33along with philanthropy, Scott,
- 5:35that then supports the academic mission
- 5:37for teaching the next generation of leaders
- 5:40for doing groundbreaking research.
- 5:42Some of that actually makes it from the bench to the bedside
- 5:46and leads to new models of care that further our reputation,
- 5:49that enhance the clinical care, and the cycle goes on.
- 5:52And that's something you can only do
- 5:54at a strong academic medical center.
- 5:56Steve, I've heard you talk in the past
- 5:58about our being in a golden age of medicine,
- 6:01and I was wondering if you could
- 6:03share with this amazing audience, what do you mean by that?
- 6:07And why are you so excited about
- 6:09what's going to be coming over the next 10 years?
- 6:12Well, it is a golden age,
- 6:15but I will also caveat it's kind of the best of times, worst of times.
- 6:18We know that the healthcare delivery
- 6:20system is broken and people have trouble
- 6:24getting access, affordable,
- 6:25equitable care, and we're working on that.
- 6:28But the scientific advances are so close.
- 6:32And with AI becoming closer every day,
- 6:34we're getting close to understanding
- 6:36the very basic
- 6:38molecular mechanisms of disease to develop drugs
- 6:42to treat and cure diseases like Alzheimer's.
- 6:45So we hope that when we talk to our medical students,
- 6:49the things that they're going to be able to do for
- 6:51their patients are unprecedented
- 6:53for the rest of the history
- 6:55of doctors, and it's such a great time for them
- 6:57to come in and practice medicine and care for patients.
- 7:01Paul, I
- 7:02think that might be a great segue to the research
- 7:05that you've been doing in the important clinical work.
- 7:08There's so many ways to, to
- 7:11start the conversation.
- 7:12But before I was talking about
- 7:14how many years you've been, you've spent researching.
- 7:17What, what changed?
- 7:19What, what has changed in the last few years
- 7:23that's made you more excited than ever
- 7:26about being able
- 7:28to create a cure for Alzheimer's?
- 7:31Yeah.
- 7:31So as you’ve pointed out, I'm
- 7:33pretty old.
- 7:38You said you started when you were 10 years old, so I ...
- 7:40that's, I’m just ...
- 7:42It happens that my career started
- 7:45when the idea of treating Alzheimer's started.
- 7:48So in a sense, that was a lucky match of my beginnings
- 7:53in academic medicine and, and a field
- 7:56that was just getting started.
- 7:58It was getting started because it was in the ‘70s
- 8:02that we first recognized that Alzheimer’s disease
- 8:05is a hugely prevalent disorder.
- 8:08One of the biggest unsolved medical issues
- 8:12that there is worldwide.
- 8:14We used to say, all the people
- 8:16that we now identify as having Alzheimer’s, we used to say it's
- 8:20hardening of the arteries, it's senility,
- 8:23it's nothing you can do.
- 8:24It was only in the ‘70s that we realized, no,
- 8:27this is a specific disease.
- 8:29It's got a specific
- 8:31abnormalities in the brain.
- 8:32It's everywhere. It's devastating.
- 8:35We need to do something.
- 8:37I finished my train,
- 8:39my endless training in, in 1985.
- 8:42And in 1985,
- 8:45we were just starting to say,
- 8:47OK, it's a disease.
- 8:50It's prevalent.
- 8:52We need to do something about it.
- 8:54And at that point,
- 8:56that's, that was a kind of
- 8:58a world-shaking idea
- 9:01because nobody had thought you could treat memory.
- 9:04That memory wasn't like pain
- 9:05or a broken bone,
- 9:07wasn't something that we thought you could treat.
- 9:10But the colleagues that I learned from
- 9:13as I was getting started really thought,
- 9:16you know, there should be something we can do about this.
- 9:19And they looked at the brains,
- 9:21they saw the plaques and tangles that Alzheimer had described.
- 9:24And they said, well,
- 9:27what actually causes the memory problem?
- 9:30And they said, well, it's communication between brain cells
- 9:33that's across something we call synapses.
- 9:36And it involves chemicals.
- 9:37And one chemical in particular, acetylcholine.
- 9:41And that there's not enough acetylcholine in the brain.
- 9:44And they started to think,
- 9:46how can we boost acetylcholine?
- 9:48It's a very interesting story.
- 9:49The, the end point is that they were right.
- 9:52And that by boosting acetylcholine in the brain,
- 9:55which we do with drugs like Aricept that you may have heard of,
- 9:59which was developed starting in the ‘80s
- 10:02based on boosting this chemical,
- 10:04that it relieves the memory symptoms a bit.
- 10:07But what we found out immediately
- 10:09in the late ‘80s was that Aricept helps
- 10:12the symptoms, doesn't do anything about the plaques
- 10:15and tangles, does not change the disease.
- 10:19Everybody with the disease
- 10:20gets worse at the same rate,
- 10:22whether they're on or off Aricept, and they all die
- 10:26a terrible death
- 10:28of end-stage dementia.
- 10:29So that's really when I joined
- 10:33the Alzheimer's community.
- 10:35And my task and my colleagues’ tasks,
- 10:39our primary task was moving
- 10:42beyond the Aricept-type drugs to drugs
- 10:45that would get at the disease itself.
- 10:49Not the symptoms, not memory impairment,
- 10:52but the disease itself.
- 10:54The plaques and tangles.
- 10:56And your question was really,
- 10:59why did it take you so long?
- 11:01And that's what I'm, that's
- 11:02what I'm trying to get to.
- 11:04So it took us so long
- 11:07because we did not have the tools to enable us
- 11:12to develop drugs
- 11:13that could get at the plaques and tangles.
- 11:16Plaques and tangles are microscopic.
- 11:18You can't see them on a CT scan.
- 11:21You can't see them on an MRI scan.
- 11:24You can't see them on a physical examination.
- 11:27You can't see them, period.
- 11:29That's what we wanted to treat,
- 11:32but we couldn't see what we were doing.
- 11:34Normally, let's say
- 11:36you're developing a drug for pain or for high blood pressure.
- 11:39You give a little.
- 11:40You see if the blood pressure comes down.
- 11:42You give it a little bit more.
- 11:43You weigh the results in terms
- 11:45of blood pressure drop with side effects.
- 11:47It's a rational development process.
- 11:50When you can't see what you're doing,
- 11:53and the memory symptoms fluctuate
- 11:55all over the place, you're shooting blind.
- 11:58And that was basically
- 12:01four decades of negative trials.
- 12:03We looked for clues from,
- 12:06you know, which people are more at risk,
- 12:08which people seem to not get the disease.
- 12:10That's epidemiology.
- 12:12All those clues were completely wrong
- 12:15because they were confounded by issues
- 12:18like people who have access to
- 12:20drugs are also better educated, higher
- 12:23socioeconomic status, meaning better access to medical treatment.
- 12:27They were healthier.
- 12:28That's why they were doing better,
- 12:30not because the drugs we were looking at,
- 12:33and that includes statins
- 12:35and estrogen and anti-inflammatory drugs.
- 12:39All these ideas we had that were just wrong
- 12:41based on flawed epidemiology because we couldn't
- 12:45see what we were doing, so we couldn't have a rational pathway.
- 12:48I'm getting to the answer. So
- 12:52what's happened in the
- 12:53last five years is,
- 12:56and actually it's not five
- 12:58years, it's started really in 2004
- 13:01with amyloid PET scanning, and then in 2012 with tau PET scanning.
- 13:07And then especially in the last five years,
- 13:10with accurate blood tests
- 13:12that show us what's happening in the brain.
- 13:16With these tools, these new imaging tools,
- 13:18so not MRI or CT, but
- 13:20molecular imaging with PET scans that we,
- 13:23that show us the plaques and tangles,
- 13:25we could develop ideas
- 13:28based on work in the laboratory
- 13:30about what a plaque is made of
- 13:32and what a tangle is made of.
- 13:34And we could test these ideas and see what we're doing.
- 13:37Give a little bit, see if the amyloid is going down
- 13:40by doing repeated amyloid PET scans.
- 13:43See if the tau is, the tangles are getting better by doing
- 13:46repeated tau PET scans.
- 13:49And now we can identify
- 13:51people accurately and measure their plaques
- 13:54and their tangles, all with blood tests.
- 13:56Just in the last five years,
- 13:59that has changed everything.
- 14:01It means that we can now
- 14:02highly, accurately identify people with Alzheimer's.
- 14:06Before that, we couldn't, and up
- 14:10to a third of the people in our trials didn't have Alzheimer’s disease.
- 14:14Try developing a drug for a disease
- 14:16that you can't identify.
- 14:18It's, it's just not easy.
- 14:20So looking back, yeah, of course we failed.
- 14:23The hours and the thousands of volunteers
- 14:27at the effort, you know, it was futile.
- 14:30But now we have the tools.
- 14:31And the reason we have the tools is that we started
- 14:34to get together and work together.
- 14:37That collaboration,
- 14:39standardizing PET scanning,
- 14:41standardizing cognitive assessments,
- 14:44working together to standardize blood
- 14:47testing gave us the tools that we need.
- 14:50We were able to follow large numbers of people
- 14:53longitudinally with these new tools.
- 14:56We were able for the first time to understand
- 14:59what this disease looks like,
- 15:01which is completely different from what we thought.
- 15:04We used to think it's a seven-year
- 15:06period of dementia to death.
- 15:08Now we know this is a disease of over
- 15:1025 years.
- 15:12That starts with a long asymptomatic phase
- 15:15when things start to go wrong in your brain,
- 15:17but your brain is able to com-, to compensate.
- 15:21And it's only when the compensatory mechanisms fail
- 15:24that you start to lose your memory,
- 15:26very late in the disease process.
- 15:29We could see the plaque starting
- 15:3120, 25 years before the end of the disease.
- 15:34We could see the tau tangles
- 15:36starting about 15 years before the end.
- 15:39We could measure everything.
- 15:41We could rationally develop drugs.
- 15:44That has simply changed everything.
- 15:46We work together.
- 15:47We share data. We share ideas.
- 15:50We work with the academic community
- 15:52and with companies and with regulators.
- 15:54And by working together with these tools,
- 15:57we've had a rational development
- 16:01of candidate drugs leading to drugs on the market.
- 16:04And now we can effectively slow the disease down
- 16:08with drugs available around the world.
- 16:11And we have clear paths
- 16:14to improve therapy,
- 16:16to earlier treatment and more effective
- 16:18therapy, combination therapies to do more,
- 16:22and primary prevention of the disease.
- 16:25Long-winded, I'm sorry, but that's my answer.
- 16:28And.
- 16:32And just to add,
- 16:34when these drugs, before they come to market,
- 16:36the major clinical trials come through the Epstein
- 16:39Alzheimer’s Treatment Research Institute.
- 16:45Amazing, Paul and Steve.
- 16:49As you said,
- 16:50it took so many years to just understand
- 16:53the development of the disease
- 16:55and then to develop the imaging and other tools
- 16:58needed to see what was happening
- 17:00physiologically and such that you could then
- 17:03determine whether Tylenol or whatever,
- 17:06all the other different things
- 17:08that have been thrown out there as possible
- 17:10cures or preventative drugs, worked or didn't work.
- 17:13And as you said, most of these drugs didn't work.
- 17:16And then you found some drug candidates
- 17:19that do seem to slow the progression of the symptoms.
- 17:22And tell us just briefly
- 17:24about the clinical trial that, or one of the,
- 17:27some of the clinical trials you're working on that aim
- 17:31to show that
- 17:33by administering these drugs,
- 17:37while an individual
- 17:39is a pre-symptomatic,
- 17:42but we know based on their blood test
- 17:44that they're going to develop the disease.
- 17:47There's
- 17:48this possibility that we can prevent that person from ever
- 17:51exhibiting Alzheimer's.
- 17:54It's going to be a little bit long of an answer again.
- 17:56OK.
- 17:58So it was in the mid-2010s
- 18:03when things, everything came together.
- 18:05So as I said, we developed a PET in 2004,
- 18:08tau PET in 2012.
- 18:11And that allowed us to launch some studies
- 18:14of really strong candidate drugs
- 18:17not based on epidemiology,
- 18:19that has always led us astray,
- 18:21but based on understanding
- 18:24the pathways that lead to amyloid,
- 18:26which is the substance in plaques, and tau,
- 18:30which is the substance in tangles.
- 18:32So we had strong
- 18:35targets that we understood specifically,
- 18:38and we developed some strong candidate drugs.
- 18:42And these drugs were antibodies.
- 18:44So, you know, antibodies
- 18:46are what we make to fight off
- 18:48bad things like bacteria and viruses.
- 18:52But antibodies can actually be designed
- 18:55in a laboratory to target anything,
- 18:59particularly proteins.
- 19:01So antibodies typically bind
- 19:03to proteins and enable the body to clear them.
- 19:06And that's how we fight viruses,
- 19:08and that's how we fight bacteria.
- 19:10Well, both the plaques
- 19:12and the tangles are made of protein.
- 19:15And what we learned from these
- 19:17collaborations in all this imaging was that it's amyloid
- 19:21that starts first, and amyloid drives the disease.
- 19:24So we started to focus on antibodies that we could manufacture,
- 19:29called monoclonal antibodies,
- 19:31that would bind to amyloid.
- 19:34And we started to test them
- 19:36in a rational way, doing small dose
- 19:40response studies covering a wide range of doses.
- 19:43And we found that if we got the dose of these antibodies
- 19:46high enough, the plaques went away.
- 19:49I mean, it was amazing.
- 19:51The plaques went away.
- 19:53This was a paper published in 2016,
- 19:56and it just blew us all away,
- 19:59that, I was working at the time with Biogen,
- 20:02that was the company that did this first study,
- 20:04and this drug could just get rid of all your plaques
- 20:07and make your PET scan normal.
- 20:09And it seemed to be helping people.
- 20:11And that's when I thought, OK,
- 20:14everything is great, we're going to win this.
- 20:17Now, things got complicated.
- 20:19I'm not going to go into that because I'm already speaking too much.
- 20:22But let me just say that aducanumab, that drug failed.
- 20:25It failed because mistakes were made and,
- 20:29but the ideas were there,
- 20:31the methods of testing were there.
- 20:34And we developed additional drugs,
- 20:36and specifically lecanemab.
- 20:38Those are anti-amyloid monoclonal antibodies
- 20:42that we manufacture
- 20:44and infuse or inject into people.
- 20:48They get into the brain.
- 20:50They bind to the plaques.
- 20:51The plaques go away because the natural defense mechanisms in the brain
- 20:56can clear the plaques once they're surrounded
- 20:58by, by these antibodies.
- 21:01So we built on that first study.
- 21:03We got two more drugs.
- 21:05And we found in large studies
- 21:07that, without question,
- 21:09absolutely proven, cannot be doubted.
- 21:12I say that because there was a book that came out last year
- 21:15doubting this, so cannot be doubted by, by
- 21:19anybody who's really paying
- 21:20attention that these drugs work.
- 21:22Now, the first studies were done in symptomatic
- 21:26Alzheimer's disease.
- 21:28Early symptoms, but symptoms.
- 21:30Now, if you remember what I said a few minutes ago,
- 21:33symptoms don't start until 15
- 21:35to 20 years into this illness.
- 21:38And at that point, removing the amyloid
- 21:40only slows the disease by about 30%.
- 21:44That's what the drugs on the market do.
- 21:46They slow the disease by 30%.
- 21:48And you can say that that's not much.
- 21:51Actually, it's a lot.
- 21:53It means that
- 21:55if you were to treat someone
- 21:56over the course of the disease for which these drugs
- 22:00were designed and work,
- 22:02that's about a six-year period.
- 22:04You're saving people two years for the rest of their lives,
- 22:07meaning a two-year delay,
- 22:09a two-year delay
- 22:10in losing your ability to drive,
- 22:12losing your ability to work, losing your ability to live independently,
- 22:16losing your ability to recognize your family
- 22:19and your life.
- 22:21So two years is a big deal.
- 22:23It's just not enough.
- 22:25We need to stop the disease altogether.
- 22:27Now, the big idea that we had
- 22:30and that we developed the methodology for
- 22:33was using all these tools,
- 22:36the PET scans especially,
- 22:38and now the blood tests
- 22:40to identify people
- 22:43while they were clinically entirely normal, no
- 22:46symptoms, and pull the amyloid out then
- 22:49before there's irreversible damage to the brain,
- 22:52which is what it leads to the actual symptoms.
- 22:56That's the study that we have underway now.
- 22:58It's a huge international study
- 23:00that, that we designed
- 23:02and we are running.
- 23:04It's funded by NIH
- 23:06in collaboration with the maker of lecanemab,
- 23:08which is Eisai Pharmaceuticals.
- 23:11And we screened 20,000 people
- 23:13and enrolled 1,600 people,
- 23:16and they're being treated for four years.
- 23:19It's all enrolled.
- 23:19We have two years to go.
- 23:21We are very optimistic that this will be
- 23:24a major advance on the 30% slowing,
- 23:28because when we look back at the trials
- 23:30we did, those who started the drug earliest
- 23:33within the symptomatic phase, phase
- 23:36had the biggest effect.
- 23:37It's what makes sense.
- 23:39Earlier treatment before there's damage, better effect.
- 23:43So we really think that's going to be
- 23:45a huge step forward.
- 23:47And you only have to wait two more years for that.
- 23:52Yes or no question.
- 23:56Is the
- 23:57hope that through the clinical trials
- 24:00that, that you're conducting
- 24:01and this idea that you just described, sometime
- 24:05as early as within the next 10 years,
- 24:08someone could take a blood test to determine
- 24:11whether they're going to have Alzheimer’s,
- 24:14and before they are symptomatic,
- 24:17they can take a pill
- 24:19like a statin and never get the disease?
- 24:23Yeah.
- 24:23So this is definitely going to happen.
- 24:26So, so the answer is yes.
- 24:27Does that work?
- 24:36Did you want me to elaborate?
- 24:37I don't know.
- 24:38Yes, and ...
- 24:39So, so, we, the blood tests have been great.
- 24:45And now they're approved
- 24:47by the FDA for checking
- 24:49whether someone with memory symptoms has Alzheimer’s disease.
- 24:52What we've been doing here
- 24:54is studying them
- 24:56in the population, in the trial
- 24:57I just described, which are people before symptoms.
- 25:00And we have found that we can identify the disease
- 25:04as accurately as PET
- 25:06scans, as amyloid and PET scans,
- 25:09just with simple blood tests
- 25:11that we can do here at ATRI.
- 25:13And that has allowed us
- 25:16to evaluate the disease
- 25:19before the onset of symptoms
- 25:21and find out
- 25:23that we can actually use these blood tests
- 25:25not to identify
- 25:27people with the disease,
- 25:29but actually identify people before
- 25:31they will get the disease.
- 25:33And this is work that we're just doing now.
- 25:36But even in this past week,
- 25:40we have had major advances proving
- 25:44that we can accurately
- 25:46use these blood tests
- 25:48to identify people years before
- 25:52even the accumulation of plaques.
- 25:54OK.
- 25:55So that's essential that we have the tool.
- 25:58We're still, we're still refining it,
- 26:00but we know we are, we have it.
- 26:03We have the tools to identify
- 26:05people years before,
- 26:07not the onset of symptoms, years
- 26:09before the onset of plaques and tangles.
- 26:12And we will be able to do that
- 26:14with an inexpensive blood test that anybody can get,
- 26:18just like a cholesterol test.
- 26:21We will start, we can see that
- 26:23we can predict this starting at about age 50.
- 26:27So what do we do about it when we identify it?
- 26:29Well, we know now the precise
- 26:34biochemical beginning of the disease,
- 26:37and it's about the way
- 26:39proteins are chopped up in your brain.
- 26:42There are normal pathways.
- 26:44The pathways become skewed by the disease
- 26:48and the enzymatic breakdown,
- 26:51the chopping up of these proteins, becomes abnormal.
- 26:54And we have drugs that precisely fix
- 27:00the abnormal
- 27:01chopping of these proteins.
- 27:03So what I'm saying is
- 27:05we now have all the tools we need.
- 27:08We still have work to do,
- 27:10but we have all the tools, tools we need.
- 27:12So that I can say with confidence
- 27:15that in the coming years, five, seven,
- 27:19less than 10 years,
- 27:21we will be able to begin
- 27:24having blood tests every year
- 27:26for everybody starting at age 50.
- 27:30And identify those who will get Alzheimer’s
- 27:34without treatment and fix the problem,
- 27:37just like you take a statin now for cholesterol.
- 27:40Except that with a statin,
- 27:43you have to treat about 50 people
- 27:45to get one who has benefit.
- 27:47We understand this disease so much better
- 27:51than we understand cardiovascular disease
- 27:54that we will be able to treat one or two people
- 27:57to save a case of Alzheimer’s disease.
- 28:01We will be able to knock down this disease
- 28:03and essentially eliminate it
- 28:05for everybody who has access
- 28:08just to simple, low-cost
- 28:10blood tests and the treatment,
- 28:11because we have the drugs, are pills.
- 28:21All right, Dr.
- 28:22Steve Shapiro, Dr.
- 28:23Paul Aisen, thank you so much.